Amorepacific's authentic derma brand, AESTURA, has garnered significant acclaim following its presentation of pioneering sensitive skin research at the Personal Care and Homecare Ingredients (PCHi) 2025 trade show in Shanghai, China.
The presentation was delivered by Dr. Yuan Chao, a newly appointed member of the prestigious Young Scientist Committee (YSC), an initiative of Amorepacific's China R&D Institute, and Chief Physician at the Shanghai Skin Diseases Hospital. Dr. Chao illuminated the development and application of DermaON™, AESTURA's core ceramide capsule technology, under the compelling theme of a △ 3rd Generation Ceramide-based solution for restoring the barrier of sensitive skin.
The underlying research led to the creation of the specialized DermaON™ capsule, born from the discovery of distinct metabolic differences between sensitive and non-sensitive skin. This remarkable capsule technology bio-mimetically reproduces the skin's natural lamellar structure, achieving exceptional stability and ensuring sustained efficacy for over 18 hours.
This patented ingredient is the cornerstone of the AESTURA ATOBARRIER365 Cream, where it has proven its exceptional capacity for skin barrier improvement and long-lasting hydration. This flagship product holds numerous accolades, including five consecutive Olive Young Awards and securing the number one position in the Cream category for 2024.
AESTURA, which officially entered the Chinese market in August of this year with a focus on local e-commerce platforms, continues to advance its research on sensitive skin barrier enhancement in collaboration with dermatological experts from across the globe, including China, the United States, and Canada. The brand is actively amplifying its presence on the international stage, expanding its collaborations with global dermatologists through its participation in the 124th Annual Meeting of the Japanese Dermatological Association this past May, and a brand presentation at the Canadian Dermatology Association (CDA) conference in June.